Baird Maintains Positive Outlook on Twist Bioscience
Baird has reaffirmed its strong support for Twist Bioscience (NASDAQ: TWST), declaring an Outperform rating and setting a price target of $46.00. The financial firm's analyst has closely observed the trends in the company’s Express Genes service, particularly the pricing strategies in place.
Recent findings indicated that the average premium charged to academic institutions in October has remained stable at about 42%, with a slight decrease from approximately 43% in September. This stable performance in pricing provides some insights but does not lead the analyst to make firm conclusions about overall revenue from synthetic genes or the cumulative gross margin percentage for Twist Bioscience.
Despite the minor reduction in premiums since September, the analyst perceives the sustained elevated pricing as a positive sign of ongoing demand for the company's diverse offerings. For those seeking more detailed insights, Baird encourages interested parties to reach out for additional datasets that could shed light on the factors shaping their projections for Twist Bioscience.
Company Overview and Financial Highlights
Twist Bioscience is renowned for its synthetic DNA manufacturing services, which cater to a variety of sectors, including medical research, agricultural biology, and industrial chemicals. Analysts frequently evaluate the company's stock performance based on numerous factors such as product demand, competitive pricing strategies, and market dynamics.
In a significant development, Twist Bioscience recorded a remarkable 28% increase in year-over-year revenue in the third quarter, with total earnings hitting $81.5 million. Additionally, the company's gross margin saw an uptick to 43.3%, with targets set to surpass 50% by the end of fiscal 2025. Looking ahead, the anticipated revenue for the fourth quarter is projected to be between $82 million and $83 million, which translates to an expected 27% total revenue growth for the fiscal year.
Recent Corporate Changes
Twist Bioscience has also made notable changes within its executive team. James Thorburn has transitioned into a strategic advisory role, providing consulting services at $25,000 per month. Alongside this, Mike Fero, Ph.D., has been appointed as the new Chief Information Officer, bringing over 30 years of experience across startups, software development, and deep-tech industries.
Under Baird’s continued watch, Twist Bioscience has retained its Outperform rating due to the consistent demand observed in its Express Genes pricing premiums. This onward trajectory reflects ongoing interest from both the academic and industry sectors.
Innovation and Product Development
Twist Bioscience has been expanding its offerings, now delivering gene fragments up to 5.0 kilobases in length. Moreover, in collaboration with bitBiome Inc., the company has introduced the Transaminase Enzyme Screening Kit, providing a more sustainable option for synthesizing chiral amines essential in drug manufacturing.
Performance Insights and Investor Sentiment
Twist Bioscience's financial metrics further enrich Baird's favorable analysis. Data indicates that the company experienced significant revenue growth, with an increase of 25.37% over the past year, totaling $295.21 million. This growth aligns with Baird's observations about the stable demand for its products, despite slight fluctuations in pricing premiums.
Additional insights reveal that TWST has enjoyed a notable return over the past week and an impressive annual return of 160.17%. Such performance reinforces the optimism surrounding Baird's Outperform rating.
It is crucial to acknowledge that TWST has not been profitable over the past twelve months, with an operating income margin of -64.34%. This financial reality explains why analysts are not expecting the company to achieve profitability this year.
Frequently Asked Questions
What is Baird's opinion on Twist Bioscience?
Baird maintains an Outperform rating on Twist Bioscience, believing in its growth potential and a price target of $46.00.
What recent financial results did Twist Bioscience report?
In its fiscal third quarter, Twist Bioscience reported a 28% year-over-year revenue increase, totaling $81.5 million.
Who has recently joined Twist Bioscience's leadership team?
Mike Fero, Ph.D., has been appointed as the new Chief Information Officer, and James Thorburn has transitioned to a Strategic Advisor role.
What product innovations is Twist Bioscience focusing on?
The company expanded its DNA synthesis capabilities, including the launch of the environmentally friendly Transaminase Enzyme Screening Kit.
How has Twist Bioscience performed in the stock market?
Twist Bioscience has shown a significant annual return of 160.17%, reflecting positive investor sentiment despite its current non-profitable status.
